THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 34, pp. 22890 –22894, August 22, 2008 © 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

Identification of Intact Protein Thiosulfinate Intermediate in the Reduction of Cysteine Sulfinic Acid in Peroxiredoxin by Human Sulfiredoxin*

Received for publication, June 19, 2008, and in revised form, June 30, 2008 Published, JBC Papers in Press, June 30, 2008, DOI 10.1074/jbc.C800124200 **Thomas J. Jo¨ nsson**‡ **, Allen W. Tsang**§ **, W. Todd Lowther**‡1**, and Cristina M. Furdui**§2

From the ‡ *Center for Structural Biology and Department of Biochemistry and the* § *Section on Molecular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157*

The reversible oxidation of the active site cysteine in typical 2-Cys peroxiredoxins (Prx) to sulfinic acid during oxidative stress plays an important role in peroxide-mediated cell signaling. The catalytic retroreduction of Prx-SO₂ by sulfiredoxin **(Srx) has been proposed to proceed through two novel reaction intermediates, a sulfinic phosphoryl ester and protein-based thiosulfinate. Two scenarios for the repair mechanism have been suggested that differ in the second step of the reaction. The attack of Srx or GSH on the Prx-SO2PO3 ² intermediate** would result in either the formation of Prx-Cys-S(=O)-S-Cys-Srx or the formation of Prx-Cys-S(=O)-S-G thiosulfi**nates, respectively. To elucidate the mechanism of Prx repair,** we monitored the reduction of human PrxII-SO₂ using rapid **chemical quench methodology and electrospray ionization time-of-flight mass spectrometry. An 18O exchange study revealed that the Prx sulfinic acid phosphoryl ester is rapidly** formed and hydrolyzed $(k = 0.35 \text{ min}^{-1})$. Furthermore, we ob**served the exclusive formation of a thiosulfinate linkage between** Prx and Srx ($k = 1.4$ min⁻¹) that collapses to the disulfide-bonded S rx-Prx species ($k = 0.14$ min⁻¹). Thus, the kinetic and chemical **competences of the first two steps in the Srx reaction have been demonstrated. It is clear, however, that GSH may influence thiosulfinate formation and that GSH and Srx may play additional roles in the resolution of the thiosulfinate intermediate.**

Proteineous Cys residues play a key role in the redox regulation of biological systems due to the wide range of oxidation states that sulfur can occupy $(-2 \text{ to } +4)$ $(1, 2)$. Most Cys undergo only small, reversible changes in oxidation state as exemplified by thiol-disulfide exchange reactions $(-2 \text{ to } -1)$ (3, 4). Remarkably, one Cys of the eukaryotic, typical 2-Cys peroxiredoxins $(Prx)^3$ has been shown to transition through five oxidation states. During the catalytic reduction of H_2O_2 , peroxynitrite, and alkyl hydroperoxides, the peroxidatic Cys $(Cys-S_pH, -2)$ is oxidized to the sulfenic acid (Cys-S_pOH, 0) (5). This activated moiety subsequently reacts with the resolving Cys $(Cys-S_RH)$ of the other Prx subunit within the homodimer to form an intermolecular disulfide bond (Prx-Cys- $S_{p}-S_{R}-Cys-Prx, -1$). This disulfide bond is readily reduced by an exogenous reductant such as thioredoxin (Trx) (6). During oxidative stress, however, a burst of peroxide can overwhelm this system and hyperoxidize the sulfenic acid intermediate to form a stable sulfinic acid (Cys-S_PO₂, +2). The resulting diminished peroxidase capacity of the cell has been thought to locally increase peroxide levels and mediate signaling events (7). In this context, human PrxII inactivation promotes cell cycle arrest, which is resumed once the Prx molecule is returned to the reduced state (8). The unique reduction of the sulfinic moiety by the enzyme sulfiredoxin (Srx) has been shown to play an important regulatory role in peroxide-mediated transcriptional activation in *Schizosaccharomyces pombe* (9, 10).

The Srx retroreduction reaction requires ATP, Mg^{2+} , a conserved active site Cys (Cys-99 in human Srx, hSrx), and an exogenous thiol reductant, such as GSH or Trx. The crystal structure of the Srx-ATP·Mg²⁺ complex (PDB 3CYI) coupled with an analysis of the phosphorylation status of Srx and Prx variants supports that the first step of the reaction (Fig. 1) involves the direct attack of the Cys-sulfinic acid moiety onto the γ -phosphate of ATP (11) rather than an intervening transfer step from Srx (12). The resulting sulfinic phosphoryl ester $(Prx\text{-}SO_2PO_3^{2-})$ is transient and thought to lead to an intermolecular thiosulfinate intermediate (*i.e.* an disulfide S-monoxide with $+1$, -1 oxidation states; step 2) either with Cys-99 of Srx (Prx-Cys-S_p(=O)–S-Cys-Srx; path 1) or with GSH (Prx-Cys-S_p $(=O)$ –S-G; path 2) (12, 13). These thiosulfinates could then be reduced by GSH to release $Prx-Cys-S_pOH$ and either Srx-S–S-G or G-S–S-G (step 3).

Over the last years, mass spectrometry (MS) has emerged as an important tool for the monitoring of both chemical and enzymatic reactions. These methods rely on either continuous flow and quenching through desolvation (time-resolved MS) or chemical quenching followed by direct injection of the quenched reaction mixture into the mass spectrometer (14– 20). In this report, we investigated the human Srx reaction mechanism using rapid chemical quench methodology and electrospray ionization time-of-flight MS (ESI-TOF MS). We found that Prx sulfinic phosphoryl ester formation was revers-

^{*} This work was supported, in whole or in part, by National Institutes of Health Grant R01GM072866 (to W. T. L.). This work was also supported by American Heart Association Postdoctoral Fellowship 0725399U (to T. J. J.) and American Heart Association Grant SDG 0730069N (to C. M. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in

accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ¹ To whom correspondence may be addressed: Center for Structural Biology and Dept. of Biochemistry, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157. Tel.: 336-716-7230; Fax:
336-777-3242; E-mail: tlowther@wfubmc.edu.

² To whom correspondence may be addressed: Section on Molecular Medicine, Dept. of Internal Medicine, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157. Tel.: 336-716-2697; Fax: 336-716-1214; E-mail: cfurdui@wfubmc.edu.

³ The abbreviations used are: Prx, peroxiredoxin; Srx, sulfiredoxin; h, human; Csd, Cys sulfinic acid; MS, mass spectrometry; ESI-TOF-MS, electrospray ionization time-of-flight MS; DTT, dithiothreitol; WT, wild type.

FIGURE 1. **Comparison of the proposed sulfinic acid reduction mechanisms of Srx.** *Path 1* represents the mechanism originally proposed by Biteau *et al.* (13). *Path 2* incorporates modifications to the reaction pathway as suggested by Jeong *et al.* (12). *Step 1* involves the formation of the sulfinic acid phosphoryl ester intermediate. In *Step 2* of the reaction, the addition of a thiol group leads to the formation of different thiosulfinate intermediates. This intermediate is subsequently resolved by GSH in *Step 3*. The resulting sulfenic acid form of Prx could then go on to react with Srx, GSH, and the resolving Cys of the adjacent Prx molecule to form Prx-S_P–S-Srx, Prx-S_P–S-G, Prx-S_P–S_R-Prx species.

ible as indicated by ^{18}O exchange. A thiosulfinate linkage between Prx and Srx was readily formed, and upon collapse of this intermediate, an increase in the disulfide-bonded Srx-Prx species was observed, proving the kinetic competency of this species. These results clarify the initial steps of the reaction mechanism but also raise questions as to the role of GSH, particularly within the cellular context.

EXPERIMENTAL PROCEDURES

Protein Preparation and Modification—Truncated versions of human Srx, the wild-type engineered truncation of hSrx (ET-Srx, residues 32–137) and the C99A mutant, were expressed in C41(DE3) *Escherichia coli* cells from a pET19 vector (Novagen) derivative containing a PreScission protease (GE Healthcare) cleavage site between Srx and the N-terminal His tag. The proteins were purified using nickel affinity and size-exclusion chromatography after the removal of the His tag (21). Histagged human PrxII containing two point mutations (C70S and C172S, hPrxII-C2S) was also expressed in C41(DE3) cells and purified in the presence of 5 mm β -mercaptoethanol and 2 mm dithiothreitol (DTT) during the nickel affinity and size exclusion steps, respectively. The sulfinic acid form of hPrxII was generated by the addition of 2 or 5 mm H_2O_2 (or in some instances, isotopically labeled $H_2^{\ 18}O_2$, Icon Isotopes, Summit, NJ) to 130 μ M PrxII-C2S in the presence of 50 mm DTT, 20 mm HEPES, pH 7.5, and 100 mm NaCl for 30 min at room temperature. Bio-Gel P6 spin columns (Bio-Rad) pre-equilibrated with 20 mM HEPES, pH 7.5, 100 mM NaCl were used to remove excess DTT and H_2O_2 . The extent of overoxidation was determined by mass spectrometry. In some cases where incomplete overoxida-

FIGURE 2. Srx-dependent incorporation of ¹⁶O in PrxII-C2S-S¹⁸O₂ sup**ports the reversible formation of PrxII sulfinic phosphoryl intermediate.** A, deconvoluted ESI-TOF MS spectra of PrxII-C2S-S¹⁸O $_2^-$ mass peak at increasing reaction times. A negative mass shift is observed in the presence of WT Srx (left panel) due to PrxII sulfinic phosphoryl intermediate hydrolysis in H₂¹⁶Obased reaction buffer. The ¹⁸O/¹⁶O exchange reaction was not observed when C99A Srx was used instead of WT Srx (*right panel*). *amu*, atomic mass units. *B*, the mass shift determined at each reaction time point was plotted against time and fit to a single exponential increase equation with an amplitude of 1.96 \pm 0.04 atomic mass units and a rate of 0.35 \pm 0.02 min⁻ .

tion was observed, the remaining Cys were reduced with 2 mm DTT for 10 min at 37 °C and then alkylated by the addition of 50 m_M iodoacetamide for 30 min. Approximately 5–10% of the protein was estimated to be alkylated.

Kinetic Assays—Reactions (50 μ l) containing 60 μ M PrxII- $C2S-SO_2^-$ or PrxII-C2S- $S^{18}O_2^-$, 1 mm ATP, 2 mm MgCl₂, 20 mm HEPES, pH 7.5, 100 mM NaCl were initiated by the addition of 40μ MWT or C99A Srx while stirring at 500 rpm at 37 °C. At the appropriate incubation time, each sample was applied to a Bio-Gel P6 spin column to remove small molecules and buffer exchange into 50 mm ammonium acetate, pH 3.0 or pH 5.0 (isotope exchange assay). For time points shorter than 30 s, rapid quench experiments were performed using a Kintek RFQ-3 rapid chemical quench instrument (Kintek Instruments, Austin, TX). The quench-flow reactions were initiated by mixing 120 μ M PrxII-C2S-SO₂, 2 mM ATP, and 4 mM Mg²⁺ in one loop (15 μ l) with 80 μ M SrxET in the other loop (15 μ l) resulting

FIGURE 3. PrxII-C2S-SO₂ reduction by WT Srx monitored by ESI-TOF MS and SDS-PAGE. A and *B*, deconvoluted ESI-TOF MS spectra of protein species present at different reaction time points. The spectra are focused on the PrxII-C2S-SO₂ (25,736 mass peak), Prx-Cys-S-S-Cys-Srx (37,723 mass peak), and Prx-Cys-S(=O)–S-Cys-Srx species (37,739 mass peak). *amu*, atomic mass units. Panel B is a closeup of the Prx-Cys-S-S-Cys-Srx and Prx-Cys-S(=O)–S-Cys-Srx species. *C*, SDS-PAGE analysis of the reaction quenched at different time points (*inset*). Formation of Prx-Cys-S–S-Cys-Srx was plotted and fit to a single exponential increase equation with a rate of 0.3 \pm 0.05 min⁻¹. D, global fit of kinetic data using KinTekSim. The plot shows the modeled kinetic profile for the Prx sulfinic phosphoryl ester intermediate and the determined kinetic profiles of thiosulfinate intermediate (Prx-Cys-S(=O)–S-Cys-Srx) and product formation (Prx-Cys-S–S-Cys-Srx) (reaction scheme and rate constants associated with the proposed kinetic steps are shown in Fig. 4).

in concentrations identical to that described above. Each reaction was quenched with 50 mm ammonium acetate, pH 3.0, and desalted prior to mass analysis. SDS-PAGE analysis of the reactions utilized 8–16% gradient gels (Bio-Rad) with non-reducing sample loading buffer and 20 mM *N*-ethylmaleimide.

Data Collection and Analysis—All ESI-TOF MS data were collected on an Agilent MSD TOF system. The operating conditions for MS analysis were as follows: positive ion mode, capillary voltage 3500 V, nebulizer gas 30 p.s.i.g., drying gas 5.0 liter/min; fragmentor 140 V, gas temperature 325 °C. The samples were injected into the ion source using a syringe pump (KD Scientific) and a $250-\mu$ l Hamilton syringe connected to the ion probe with a 50- μ m inner diameter fused silica capillary. The injection flow rate was 10 μ l/min. The averaged MS spectra were deconvoluted using the Agilent MassHunter work station software Version B.01.03. Data from the isotope exchange reactions were quantified based upon the relative mass shift (Δ) mass) in the PrxII-C2S-S18O₂ species as result of $^{18}O/^{16}O$ exchange. The Δ mass was fit to a single exponential equation $y = a(1 - e^{-kt})$ to determine the rate constant for the ¹⁸O/¹⁶O

exchange. The formation and decay of the intermolecular thiosulfinate and disulfide species were expressed as a ratio of peak intensity of the respective species relative to the constant amount of catalytically inactive iodoacetamide-labeled PrxII-C2S. Fits of data were carried out using Sigma-Plot 10.0 and KinTekSim based on a simple $A \leftrightarrow B \leftrightarrow C \leftrightarrow D$ mechanism where A is the PrxII-C2S-SO $_2^-$ substrate, B is the Prx sulfinic phosphoryl ester intermediate, C is the thiosulfinate intermediate ((Prx-Cys-S(=O)–S-Cys-Srx), and D is the Srx-Prx covalent heterodimer.

RESULTS AND DISCUSSION

Reversibility of the Phosphorylated Prx Intermediate—The mechanism of Prx sulfinic acid reduction by Srx has been proposed to proceed through two novel protein intermediates, sulfinic phosphoryl ester and thiosulfinate (Fig. 1). Previous efforts to identify these intermediates using wild-type proteins have been unsuccessful (11-13). Recently, we were able to trap a phosphorylated form of Prx where the Cys- S_P residue was mutated to Asp $(-CO_2^-)$ (11). In the study described here, the reaction mechanism of PrxII-SO $_2^-$ reduction by Srx was inves-

FIGURE 4. **Structural and kinetic intermediates along the human Srx reaction coordinate. A, the Prx-S_PO₂ moiety (***purple***), Cys sulfinic acid 52 (Csd52),** poised for an inline attack of the y-phosphate of ATP, based on the ATP·Mg²⁺·Srx (*blue*) and Srx-S–S_P-PrxI crystal structures (Protein Data Bank numbers 3CYI and 2RII) (11, 22). The resulting phosphorylated intermediate (not shown) can be readily hydrolyzed. *B*, model of the thiosulfinate intermediate between Srx and Prx. C, the crystallographically determined Prx-S_p-S-Srx disulfide-bonded complex (Protein Data Bank number 2RII). This complex could form through several steps involving reactions between the sulfenic acid form of Prx and Srx.

tigated using a combination of rapid chemical quench and ESI-TOF MS. Given the facile interchange between activated sulfur species, which could potentially complicate the interpretation of experimental data, a decision was made to remove all thiols that were not necessary for reduction of the Prx molecule. This was accomplished by using the hPrxII-C2S variant (C70S, C172S) and performing the reactions in the absence of GSH. Under these conditions, Srx, ATP, and Mg^{2+} are sufficient to repair the Prx-Cys-51- $S_PO_2^-$ moiety.

The initial control reactions were quenched at different time points by passing the samples through spin columns equilibrated with ammonium acetate ($pH < 5$) prior to MS analysis. A molecular peak corresponding to the mass of the thiosulfinate intermediate was consistently observed along with the Srx, PrxII-C2S-SO₂, and Srx-Prx species; however, there was no evidence for the presence of the Prx sulfinic phosphoryl ester intermediate. In an effort to determine the Srx requirement for the formation of the Prx phosphoryl intermediate, the isotopically labeled PrxII-C2S-S¹⁸O₂ was incubated with Srx and excess ATP and Mg^{2+} at pH 7.5, and the $^{18}O/^{16}O$ exchange reaction was monitored at different time points over a 15 min period (Fig. 2*A*). A mass decrease of 2 Da was observed in the PrxII-C2S- $S^{18}O_2^-$ molecule with the rate of mass exchange consistent with a first order rate constant of 0.35 min⁻¹ (Fig. 2*B*). A full exchange of the ¹⁸O for ¹⁶O, *i.e.* a mass decrease of 4 Da, was not observed. The ¹⁸O/¹⁶O exchange reaction was not observed when the reaction was performed at pH 5, ATP and Mg^{2+} were omitted, and the Srx C99A mutant was used (Fig. 2*A*). ATP hydrolysis in the absence of an exogenous thiol (*i.e.* GSH) is consistent with the increased level of ${}^{32}P_i$, release over the amount of sulfinic acid substrate observed by Jeong *et al.* (12). Similar to the findings described here, the use of the C99A Srx variant prevented ATP hydrolysis.

Together, these observations illustrate the necessity of phosphorylation for 18 O exchange and the reversibility of the first step of the reaction. These results are consistent with the rapid phosphorylation of the Prx sulfinic acid moiety. It is also apparent that the formation and slow hydrolysis of the sulfinic phosphoryl ester are both possibly dependent on Cys-99 of Srx. Cys-99 and the other surrounding active site residues may influence the correct positioning of the sulfinic acid moiety, associated loop residues, and water structure through hydrogen-bonding and hydrophobic interactions. Support for this notion comes from the apparent stereospecific exchange of 18O within the sulfinic acid and the geometric relationship of the γ -phosphate group of ATP within Srx that facilitates an inline attack by the Prx molecule and not Srx (11, 22). A crystal structure of the Srx-Prx-ATP Mg^{2+} complex and future time-resolved ESI-TOF MS experiments performed without chemical quenching and on the millisecond time scale will hopefully clarify this issue (15, 19, 20).

Identification of an Intact Thiosulfinate Intermediate between Srx and Prx—In the second step of the repair of Prx- SO_2^- (Fig. 1), two different thiosulfinate intermediates have been proposed. Although Biteau *et al.* (13) proposed the formation of a protein-protein thiosulfinate $(Prx-Cys-S(=O)-S-Cys-$ Srx), Jeong *et al.* (12) proposed a protein-glutathione thiosulfinate (Prx-Cys-S(=O)–SG) intermediate. In a similar approach to the isotope exchange study, we sought to identify the thiosulfinate species using ESI-TOF MS.

Although nothing is known about protein-based thiosulfinates, studies on small molecule thiosulfinates have shown that they are very reactive with other thiols and stabilized at low pH (2, 23, 24). Therefore, a reaction with the PrxII-C2S-SO₂ mutant in slight excess over Srx at pH 7.5 was rapidly quenched at different time points by the addition of ammonium acetate,

ACCELERATED PUBLICATION: *Srx-Prx Thiosulfinate Intermediate*

pH 3.0, followed by desalting on a Bio-spin column equilibrated with the same buffer. Under these conditions, we were able to observe two species with the average molecular mass of 37,723.00 \pm 0.14 and 37,739.70 \pm 0.11 Da, which correspond to Prx-S–S-Srx heterodimer (expected mass 37,723.35 Da) and the thiosulfinate-linked complex between Srx and Prx (expected mass 37,739.35 Da) (Fig. 3, *A–*C). As expected, the mass of the thiosulfinate complex was 2 Da higher when the isotopically labeled PrxII-C2S- $S^{18}O_2^-$ was used (data not shown). The disulfide and thiosulfinate species were absent when the reaction was performed with the C99A mutant of Srx.

Reactions with up to 1 mm GSH were also analyzed, and no evidence was found for the formation of a Prx-GSH thiosulfinate intermediate (data not shown). Moreover, the addition of GSH resulted in the complete disappearance of the disulfidebonded and thiosulfinate Srx-Prx species and formation of the glutathionylated adducts of Srx and Prx, 12,327.1 and 25,737.0 Da, respectively. Thus, under physiological conditions where GSH is present at $1-10$ mm, there may be a competition between Srx and GSH for the Prx sulfinic phosphoryl ester to form the thiosulfinate species. Given local concentration effects and the close proximity of Cys-99 of Srx to the Prx sulfinic moiety (11, 22), however, the attack of Srx should be efficient as suggested by the rate analyses described below. Nonetheless, it is clear that additional time- and concentration-dependent ESI-TOF MS experiments will be required to deconvolute GSH contributions to the kinetics of the Srx-Prx thiosulfinate and the putative Prx-GSH thiosulfinate formation and resolution, although the latter species could not be experimentally observed. No matter which thiolsulfinate path is taken in step 2, the result is the same, a repaired Prx molecule with regained enzymatic activity by the action of Srx.

Given that complete repair of the Prx molecule is possible without the addition of GSH, we modeled the Srx reaction using KinTekSim to validate the reaction scheme, as described under "Experimental Procedures." The rate constants for the reaction steps were determined based on the relative intensities of disulfide and thiosulfinate species (Fig. 3, *A* and *B*) and were as follows: 0.35 min^{-1} for sulfinic phosphoryl ester hydrolysis, 1.4 min⁻¹ for thiosulfinate formation, and 0.14 min⁻¹ for Prx-Cys-S–S-Cys-Srx formation. The latter rate is comparable with the rate of 0.3 min^{-1} determined by SDS-PAGE analysis (Fig. 3*C*). The resulting global fit shown in Fig. 3*D* is consistent with the rapid formation of the sulfinic phosphoryl ester ($>$ 2 min⁻¹) and the following mechanism (Fig. 4). In the absence of GSH, PrxII-C2S-SO $_2^-$ is rapidly phosphorylated to generate the sulfinic phosphoryl ester intermediate. This reaction is reversible by the attack of hydroxide ions at a rate of 0.35 min⁻¹ at pH 7.5. This equilibrium is driven forward by the thiol attack of Cys-99 in Srx at a rate of 1.4 min^{-1} to form a thiosulfinate intermediate between Srx and Prx. One additional Srx can then attack the thiosulfinate bond to generate the sulfenic acid form of Prx and Srx-S–S-Srx. Srx could also readily react with Prx-Cys-SOH to generate the observed Prx-Cys-S–S-Cys-Srx disulfide bond at a rate of 0.14 min^{-1} .

The studies described here prove the kinetic competence of the Prx sulfinic phosphoryl ester and Prx-Srx thiosulfinate intermediates and the chemical identity of the latter. Moreover,

these data coupled with previous structural analyses support a unique reaction mechanism where Srx functions as an ATP carrier and facilitator of the unfolding of the Prx active site. This process enables the sulfinic acid moiety to attack the γ -phosphate of ATP, leading to the sequential formation of the sulfinic phosphoryl ester and thiosulfinate intermediate with Srx. Collapse of the thiosulfinate can be mediated by Srx, when GSH is not included in the reaction and the Cys- S_P residue of Prx is mutated. Therefore, the contribution of these potentially important thiols to the Srx retroreduction reaction and hydrogen peroxide-mediated cell signaling will ultimately need to be evaluated. Combined kinetics and mass spectrometry methodologies are poised to answer these questions and those of other reactions with novel reaction intermediates and chemistry that have eluded conventional methods of analysis.

Note Added in Proof—Recent studies of the yeast Srx/Prx system have also led to the identification of the $Prx-Cys-S(=O)-S-Cys-Srx$ thiosulfinate catalytic intermediate (25).

REFERENCES

- 1. Giles, G. I., and Jacob, C. (2002) *Biol. Chem.* **383,** 375–388
- 2. Jacob, C. (2006) *Nat. Prod. Rep.* **23,** 851–863
- 3. Sevier, C. S., and Kaiser, C. A. (2006) *Antioxid. Redox Signal.* **8,** 797–811
- 4. Toledano, M. B., Kumar, C., Le Moan, N., Spector, D., and Tacnet, F. (2007) *FEBS Lett.* **581,** 3598–3607
- 5. Ellis, H. R., and Poole, L. B. (1997) *Biochemistry* **36,** 15013–15018
- 6. Wood, Z. A., Schröder, E., Harris, J. R., and Poole, L. B. (2003) *Trends Biochem. Sci.* **28,** 32–40
- 7. Wood, Z. A., Poole, L. B., and Karplus, P. A. (2003) *Science* **300,** 650–653
- 8. Phalen, T. J.,Weirather, K., Deming, P. B., Anathy, V., Howe, A. K., van der Vliet, A., Jönsson, T. J., Poole, L. B., and Heintz, N. H. (2006) *J. Cell Biol.* **175,** 779–789
- 9. Bozonet, S. M., Findlay, V. J., Day, A. M., Cameron, J., Veal, E. A., and Morgan, B. A. (2005) *J. Biol. Chem.* **280,** 23319–23327
- 10. Vivancos, A. P., Castillo, E. A., Biteau, B., Nicot, C., Ayte, J., Toledano, M. B., and Hidalgo, E. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102,** 8875–8880
- 11. Jönsson, T. J., Murray, M. S., Johnson, L. C., and Lowther, W. T. (2008) *J. Biol. Chem.* 10.1074/jbc.M803244200
- 12. Jeong, W., Park, S. J., Chang, T. S., Lee, D. Y., and Rhee, S. G. (2006) *J. Biol. Chem.* **281,** 14400–14407
- 13. Biteau, B., Labarre, J., and Toledano, M. B. (2003) *Nature* **425,** 980–984
- 14. Bothner, B., Chavez, R., Wei, J., Strupp, C., Phung, Q., Schneemann, A., and Siuzdak, G. (2000) *J. Biol. Chem.* **275,** 13455–13459
- 15. Furdui, C. M., Lew, E., Schlessinger, J., and Anderson, K. S. (2006) *Mol. Cell* **17,** 1–7
- 16. Gross, J. W., Hegeman, A. D., Vestling, M. M., and Frey, P. A. (2000) *Biochemistry* **39,** 13633–13640
- 17. Konermann, L., Collings, B. A., and Douglas, D. J. (1997) *Biochemistry* **36,** 5554–5559
- 18. Paiva, A., Tilton, R. F., Crooks, G. C., Liang, P.-H., and Anderson, K. S. (1997) *Biochemistry* **36,** 15472–15476
- 19. Li, Z., Sau, A., Shen, S., Whitehouse, C., Baasov, T., and Anderson, K. S. (2003) *J. Am. Chem. Soc.* **125,** 9938–9939
- 20. Li, Z., Sau, A. K., Furdui, C. M., and Anderson, K. S. (2005) *Anal. Biochem.* **343,** 35–47
- 21. Jönsson, T. J., Murray, M. S., Johnson, L. C., Poole, L. B., and Lowther, W. T. (2005) *Biochemistry* **44,** 8634–8642
- 22. Jönsson, T. J., Johnson, L. C., and Lowther, W. T. (2008) *Nature* 451, 98-101
- 23. Kice, J. L., and Rogers, T. E. (1974) *J. Am. Chem. Soc.* **96,** 8015–8019
- 24. Shen, C., Xiao, H., and Parkin, K. L. (2002) *J. Agric. Food Chem.* **50,** 2644–2651
- 25. Roussel, X., Bechade, G., Kriznik, A., Van Dorsselaer, A., Sanglier-Cianferani, S., Branlant, G., and Rahuel-Clermont, S. (2008) *J. Biol. Chem.* 10.1074/jbc.M800493200.